NASDAQ:FGENFibroGen Stock Price, Forecast & News

FibroGen's stock was trading at $35.40 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FGEN shares have increased by 4.0% and is now trading at $36.82. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for FibroGen.

FibroGen is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for FibroGen.

FibroGen Inc (NASDAQ:FGEN) announced its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.50. The biopharmaceutical company had revenue of $24.40 million for the quarter, compared to analysts' expectations of $72.58 million. FibroGen had a negative return on equity of 19.32% and a negative net margin of 42.75%. FibroGen's revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.53) earnings per share. View FibroGen's earnings history.

8 brokers have issued 12-month price targets for FibroGen's shares. Their forecasts range from $40.00 to $80.00. On average, they expect FibroGen's stock price to reach $53.29 in the next year. This suggests a possible upside of 44.7% from the stock's current price. View analysts' price targets for FibroGen.

News stories about FGEN stock have trended extremely negative on Monday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. FibroGen earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutFibroGen.

Some companies that are related to FibroGen include Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), Beigene (BGNE), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), Mylan (MYL), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), Elanco Animal Health (ELAN), Perrigo (PRGO), Ascendis Pharma A/S (ASND) and Bausch Health Companies (BHC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

(FGEN) raised $146 million in an IPO on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

FibroGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.88%), Primecap Management Co. CA (5.64%), Janus Henderson Group PLC (3.46%), State Street Corp (2.99%), JPMorgan Chase & Co. (1.89%) and First Trust Advisors LP (1.48%). Company insiders that own FibroGen stock include Christine Chung, Elias Kouchakji, James A Schoeneck, Jorma Routti, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Roberto Pedro Rosenkranz, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View institutional ownership trends for FibroGen.

FGEN stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, JPMorgan Chase & Co., Morgan Stanley, Two Sigma Investments LP, Rafferty Asset Management LLC, Bank of New York Mellon Corp, Pinnacle Associates Ltd., and Two Sigma Advisers LP. Company insiders that have sold FibroGen company stock in the last year include Christine Chung, Elias Kouchakji, K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Thomas B Neff, and Thomas F Kearns Jr. View insider buying and selling activity for FibroGen.

FGEN stock was acquired by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Janus Henderson Group PLC, BlackRock Inc., Invesco Ltd., Geode Capital Management LLC, Alliancebernstein L.P., Moody Aldrich Partners LLC, and Foresite Capital Management III LLC. View insider buying and selling activity for FibroGen.

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FGEN stock can currently be purchased for approximately $36.82.

FibroGen has a market capitalization of $3.28 billion and generates $256.58 million in revenue each year. The biopharmaceutical company earns $-76,970,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. FibroGen employs 461 workers across the globe.

The official website for FibroGen is www.fibrogen.com.

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]